⌕
Taysha Gene Therapies · TSHA · Nasdaq
Tenet 58 · Mixed
Compare
$4.00−1.48%At closeTenet 58 · Mixed
$4.00−0.06 (−1.48%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Taysha Gene Therapies (TSHA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is TSHA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 12, 2026 · 18:29 ET
Taysha Gene Therapies, Inc. (TSHA) Q3 2026 Earnings Call Transcript

Taysha Gene Therapies, Inc. ( TSHA ) Q3 2026 Earnings Call November 12, 2026 8:30 AM EST Company Participants Sean Nolan - CEO & Chairman Sukumar Nagendran - President, Head of Research & Development and Director Kamran …

TSHA −1.5% todayRead at source ↗
● MarketBeatNov 12, 2026 · 16:15 ET
Taysha Gene Therapies Q3 Earnings Call Highlights

Taysha Gene Therapies NASDAQ: TSHA expects to report pivotal trial data for its experimental Rett syndrome gene therapy TSHA-102 and provide feedback from U.S. regulators on a potential filing pathway in the first half o…

TSHA −1.5% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update

REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027…

TSHA −1.5% todayRead at source ↗
● GlobeNewsWireNov 6, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies …

TSHA −1.5% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12

DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies …

TSHA −1.5% todayRead at source ↗
● Defense WorldOct 16, 2026 · 03:41 ET
Taysha Gene Therapies (NASDAQ:TSHA) Hits New 52-Week Low – Time to Sell?

Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $3.55 and last traded at $3.58, with a volume of 6,115,201 …

TSHA −1.5% todayRead at source ↗
● Defense WorldOct 9, 2026 · 04:46 ET
Taysha Gene Therapies (NASDAQ:TSHA) versus MediWound (NASDAQ:MDWD) Head to Head Analysis

Taysha Gene Therapies (NASDAQ: TSHA - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based …

TSHA −1.5% todayRead at source ↗
● GlobeNewsWireOct 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies …

TSHA −1.5% todayRead at source ↗
● GlobeNewsWireOct 1, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies …

TSHA −1.5% todayRead at source ↗
● Seeking AlphaSep 11, 2026 · 11:11 ET
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

Taysha Gene Therapies offers a speculative opportunity, hinging on durable clinical gains, safety, and disciplined execution for TSHA-102 in Rett syndrome. TSHA's $455.4M cash runway extends into H2 2028, supporting pivo…

TSHA −1.5% todayRead at source ↗
● GlobeNewsWireSep 4, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies…

TSHA −1.5% todayRead at source ↗
● Defense WorldAug 26, 2026 · 04:01 ET
Bank of America Corp DE Has $7.50 Million Stake in Taysha Gene Therapies, Inc. $TSHA

Bank of America Corp DE raised its stake in Taysha Gene Therapies, Inc. (NASDAQ: TSHA) by 45.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund own…

TSHA −1.5% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just TSHA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.